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Three amino-acid loop extension (TALE) homeobox proteins MEIS and PBX are cofactors for
HOX-class homeobox proteins, which control growth and differentiation during embryo-
genesis and homeostasis. We showed that MEIS and PBX expression are related to cisplatin
resistance in ovarian cancer cell lines. Therefore, MEIS1, MEIS2 and PBX expression were
investigated immunohistochemically in a tissue microarray (N = 232) of ovarian cancers
and ovarian surface epithelium (N = 15). Results were related to clinicopathologic charac-
teristics and survival. All cancers expressed MEIS1, MEIS2 and PBX in nucleus and cyto-
plasm. MEIS1 and 2 only stained nuclear in surface epithelium. Nuclear MEIS2 was
negatively related to stage, grade and overall survival in univariate analyses. Additionally,
MEIS and PBX RNA expression in ovarian surface epithelium and other normal tissues and
ovarian cancer versus other tumour types using public array data sets were studied. In
ovarian cancer, MEIS1 is highly expressed compared to other cancer types. In conclusion,
MEIS and PBX are extensively expressed in ovarian carcinomas and may play a role in ovar-
ian carcinogenesis.
 2007 Elsevier Ltd. All rights reserved.1. Introduction
HOX homeobox proteins are transcription factors involved
in growth control and differentiation during embryogenesis
as well as homeostasis.1 HOX genes, when deregulated, play
important roles in oncogenesis. Their expression and
function in cancers seems to be tissue-specific.2–7 Threeer Ltd. All rights reserved
/1847; fax: +31 50 361 486
l (E.G.E. de Vries).amino-acid loop extension (TALE) homeobox proteins MEIS
and PBX function as cofactors for HOX proteins. All
vertebrate model organisms seem to have three functional
MEIS genes. Human MEIS1 and MEIS2 genes have been re-
ported in vivo, while the MEIS3 gene has only been identi-
fied in silico. Furthermore, there are four human PBX
genes.8–14.
2.
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transcription polymerase chain reaction, we have shown that
the three amino-acid loop extension (TALE) homeobox genes
MEIS1, MEIS2 and PBX3 were down-regulated in three cis-
platin resistant sub lines of the cisplatin sensitive parental
ovarian cancer cell line A2780.15 In addition, the MEIS1 gene
has been shown to be amplified and over-expressed in ovar-
ian cancers compared to normal ovarian surface epithelium
and is part of an ovary-specific gene expression profile distin-
guishing primary lung, colon and ovarian adenocarcino-
mas.16–18
As protein expression data on the HOX cofactors in ovar-
ian cancer are lacking, the aim of the present study was to
investigate MEIS1, MEIS2 and PBX protein expression in a
large set of ovarian cancers. To discover the effect of chemo-
therapy on MEIS and PBX proteins in ovarian cancers, their
expression levels were also compared between paired pre-
and post-chemotherapy tumour samples. The results were re-
lated to clinicopathologic characteristics and survival. Finally,
to compare MEIS and PBX RNA expression between normal
ovarian surface epithelium and various other normal tissues
and between ovarian cancer and various other tumour types
the public Affymetrix data sets N353 and XPO1026 were
studied.19,20
2. Material and methods
2.1. Tissue microarray
Since the early 1980s, all clinicopathologic and follow-up data
of ovarian cancer patients referred to the Department of
Gynaecologic Oncology at the University Medical Centre
Groningen (Groningen, The Netherlands) were prospectively
collected during standard treatment and follow-up and stored
in a computerised database. International Federation of
Gynaecology and Obstetrics (FIGO) staging was performed.
The patients were treated according to regional guidelines
on the diagnostic work-up, surgical and medical treatment
and follow-up.21 The surgical guidelines largely resembled
FIGO guidelines.22 New treatment regimens were adopted as
follows: platinum-based chemotherapy in early 1980s, debul-
king surgery at the end of 1980s and platinum/paclitaxel che-
motherapy since 1996. Clinical response to chemotherapy
was determined according to standard WHO criteria.23 Opti-
mal and suboptimal debulking were defined as the largest tu-
mour lesions having a diameter <2 cm orP2 cm, respectively.
Progression free survival and overall survival were calculated
from the date of primary surgery to the date of progression/
relapse or last follow-up/death due to ovarian cancer, respec-
tively. The database also contained information on the avail-
ability of tumour samples. Patients had given informed
consent for collection and storage of tissue samples in a tis-
sue bank for future research. Tumour samples were obtained
at the time of surgery and embedded in paraffin blocks and/or
frozen in liquid nitrogen and stored at )80 C.
For the present study, the database was searched for con-
secutive patients treated for epithelial ovarian cancer be-
tween 1985 and 2002 and of whom paraffin-embedded
tumour was available. All relevant data were retrieved from
the database and transferred into a separate anonymousdatabase. In this separate password protected database, pa-
tient identity was protected by study-specific, unique patient
codes. The true identity of patients was only known to two
dedicated data managers, who also have daily responsibility
for the larger database. In case of uncertainties with respect
to clinicopathologic and follow-up data, the larger databases
could only be checked through the data managers, thereby
ascertaining the protection of patients’ identity. Owing to
these precautions, according to Dutch law no further IRB ap-
proval was needed.
Eight tissue microarrays (TMAs) were constructed from tu-
mour samples of 232 ovarian cancer patients. Of 44 patients
paired tumour samples before and after first-line chemother-
apy were available. Post-chemotherapy samples were col-
lected at surgery after three or six cycles of chemotherapy
(N = 26) or at surgery for recurrent disease (N = 20). TMAswere
constructed as described in a previous study.24 Four separate
cores of 0.6 mm were retrieved from each tumour sample
(Tissue Arrayer, Beecher Instruments, Silver Spring, MD,
USA). Each TMA contained duplicate cores of 10 internal con-
trols to ensure similarity of staining between the slides. As
internal controls six tumour samples (serous, mucinous,
endometrioid, clear cell and undifferentiated ovarian carci-
noma, and an ovarian cystadenoma) and four normal tissue
samples (Fallopian tube, endometrial, endocervical and cervi-
cal tissue) were present on each TMA. As controls apart from
the TMAs, 15 paraffin blocks containing normal ovarian epi-
thelium tissue (pre- (N = 5) and post-menopausal (N = 5) ova-
ries, and ovaries prophylactically removed from women
with a BRCA1 (N = 2) and BRCA2 mutation (N = 3)), two blocks
containing proliferating endometrial tissue and two blocks
containing non-proliferating endometrial tissue were used.25
2.2. Immunohistochemistry
For immunohistochemistry 4 lm sections were cut from the
ovarian cancer TMAs and paraffin blocks containing normal
ovaries or endometrial tissue and mounted on 3-amino-pro-
pyl-ethoxy-silane coated glass slides (Sigma–Aldrich, Dies-
enhofen, Germany). All slides were stained within two
weeks from sectioning. After the sections had been dewaxed
in xylene, antigen retrieval was performed by autoclave treat-
ment; three times 5 min at 115 C in blocking reagent (2%
block + 0.2% sodium dodecyl sulphate in maleic acid, pH 6.0;
Boehringer Mannheim, Mannheim, Germany). Endogenous
peroxidase activity was blocked by incubating the slides in
hydrogen peroxidase. For MEIS1 and MEIS2, endogenous avi-
dine and biotine activity was also blocked using Blocking kit
(Vector laboratories, Burlingame, CA, USA). All primary anti-
bodies were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA): MEIS1/2 (sc-10599), MEIS2 (sc-10600) and
PBX1/2/3/4 (sc-28313). MEIS1, MEIS2 and PBX antibodies were
diluted 1:25 and sectionswere incubated overnight at 4 C. For
MEIS1 andMEIS2 the slideswere pre-incubatedwith 1.5% nor-
mal rabbit serum for 1 h at room temperature. For all wash-
ings and dilutions 0.05 M Tris-buffered saline containing
0.1% Tween-20 was used for MEIS1 and PBX, and PBS contain-
ing 1% bovine serum albumin was used for MEIS2. For nega-
tive controls the primary antibodies were omitted. PBX was
detected using a goat anti-mouse/rabbit secondary antibody
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sion+ system; DAKO, Cambridgeshire, UK). Biotinylated rabbit
anti-goat IgG ((H + L), Southern Biotechnology, Birmingham,
AL, USA) served as a secondary antibody (1:300 for 30 min at
room temperature) for MEIS1 and MEIS2. For MEIS2, 1% nor-
mal rabbit serum was added to the dilution of the secondary
antibody. ABComplex/HRP (DAKO) was applied for 30 min and
3, 3 0-diaminobenzidine was used to visualise all antigen–anti-
body reactions.
Two observers (APGC and KAH) independently scored
immunohistochemical stainings at a double-headed micro-
scope without prior knowledge of the clinicopathologic infor-
mation. The cases with a discrepant score were re-examined
with a gynaecologic pathologist (HH) until consensus wasFig. 1 – MEIS1, MEIS2 and PBX protein expression in ovarian tu
Nuclear MEIS1 expression in normal ovarian surface epithelium
epithelium. (C) Nuclear and cytoplasmic PBX expression in norm
MEIS1 expression in ovarian tumour tissue. (E) Nuclear and cyt
Nuclear and cytoplasmic PBX expression in ovarian tumour tissreached. At least two of the four core biopsies representing
each whole tumour sample had to be available for scoring.
Nuclear and cytoplasmic immunoreactivity for the MEIS and
PBX antibodies was graded as weak (0–1), moderate (2) or
strong (3). Staining intensity was assessed by visual scoring.
The stain intensity score was taken as the mean from the
2–4 biopsies that represented each tumour.
2.3. Statistical analysis
2.3.1. Immunohistochemistry data analysis
Statistical analysis was performed using the SPSS 12.0 soft-
ware package (SPSS Inc., Chicago, IL). The relationship be-
tween nuclear and cytoplasmic expression of MEIS1, MEIS2mour tissue and normal ovarian surface epithelium. (A)
. (B) Nuclear MEIS2 expression in normal ovarian surface
al ovarian surface epithelium. (D) Nuclear and cytoplasmic
oplasmic MEIS2 expression in ovarian tumour tissue. (F)
ue.










Median 59 54 60








1 39 (18) 29 (48) 9 (6)
2 52 (25) 22 (37) 29 (20)
3 104 (50) 7 (12) 97 (66)
Undifferentiated 14 (7) 2 (3) 12 (8)
Unknown 23 4 19
Histological subtype
Serous 128 (55) 13 (20) 115 (69)
Mucinous 27 (12) 18 (28) 8 (5)
Endometrioid 33 (14) 19 (30) 14 (8)
Clear Cell 17 (7) 6 (9) 10 (6)
Other 27 (12) 8 (13) 19 (12)
Debulking status
Optimal < 2 cm 111 (50) 61 (97) 48 (31)
Suboptimal P 2 cm 109 (50) 2 (3) 107 (69)
Unknown 12 1 11
First-line chemotherapy
None 36 (16) 25 (40) 11 (7)
Platinum-based 171 (76) 34 (55) 136 (84)
Non-platinum-based 17 (8) 3 (5) 15 (9)
Unknown 8 2 4
Chemotherapy-response
CRa/PRb 82 (71) 3 79 (70)
SDc/PDd 34 (29) 34 (30)
a CR, complete response.
b PR, partial response.
c SD, stable disease.
d PD, progressive disease.
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mour samples was assessed by the Wilcoxon signed rank
test. To assess the relation between nuclear MEIS1, MEIS2
and PBX protein expression and clinicopathologic character-
istics univariate logistic regression analyses were per-
formed, using MEIS1, MEIS2 and PBX as dependents,
respectively. The cut-off-point for nuclear MEIS1 (weak/
moderate or strong), MEIS2 (weak or moderate/strong) or
PBX (weak/moderate or strong) expression was decided a
priori. As independent clinicopathologic characteristics were
included; age (>59 or 659 years), stage (stage III/IV or stage
I/II), histology (serous or non-serous), grade (grade 3/undif-
ferentiated or grade 1/2 and residual disease (>2 cm or
62 cm). For MEIS2 also multivariate logistic regression anal-
ysis was performed adjusted for the variables stage, grade
and histology. To study whether nuclear MEIS1, MEIS2 and
PBX protein expression were predictive for overall survival
and progression free survival, survival curves were calcu-
lated using Kaplan–Meier analysis with assessment of sta-
tistical significance using the log-rank test. Subsequently,
to investigate whether MEIS1, MEIS2 and PBX were indepen-
dent prognostic factors, multivariate overall survival and
progression free survival analyses were performed using
Cox proportional-hazard regression models adjusted for
stage and residual tumour. P-values of 0.05 were considered
significant.
2.3.2. Public Affymetrix data set analysis
Affymetrix data for human normal tissues (N353) and sev-
eral cancer types (XPO1026 (https://expo.intgen.org/expo/
public)) were retrieved from public GEO (Gene Expression
Omnibus) data sets on the NCBI website.19,20 CEL data from
the Affymetrix GeneChip Human Genome U133 Plus 2.0 ar-
ray data sets were downloaded and intensity values and
their accompanying P-values assigned to MEIS1, MEIS2,
MEIS3 (in silico identified sequence) and PBX1–4 probe-sets
with GCOS software using the MASS5.0 algorithm. Annota-
tions for the tissue samples analysed are available from
http://www.ncbi.nlm.nih.gov/geo/query/ through their GEO
ID: GSE3526 9 and GSE210 for the N353 and XPO1026 data
sets, respectively.
3. Results
3.1. MEIS and PBX protein expression in normal ovarian
surface epithelium, primary and paired pre- and post-
chemotherapy ovarian tumours
In normal ovarian surface epithelium MEIS and PBX protein
expression were clearly visible (Fig. 1). MEIS1 and MEIS2
stained exclusively nuclear, while PBX staining was also
cytoplasmic. There were no obvious differences in staining
patterns for the three proteins neither in normal ovarian
surface epithelium from pre-menopausal women, post-
menopausal women or women with familial ovarian
cancer.
The clinicopathologic data of the 232 primary cancers
present on the TMA are summarised in Table 1. The median
follow-up time of the patients was 26 months (range: 0–213months) and the 5-year overall survival rate was 31% (118 pa-
tients died because of ovarian cancer).
MEIS1, MEIS2 and PBX protein expression were identified
in ovarian cancers (Fig. 1). Tumours showed nuclear as well
as cytoplasmic staining. All tumour sections wholly and
homogeneously stained for MEIS 1 and 2 and PBX. The per-
centage ovarian cancers per staining category for each pro-
tein are presented in Table 2. Nuclear MEIS1 and PBX
expression were strong in most of the cancers (in 90% and
74%, respectively). Cytoplasmic MEIS1 and PBX expression
were moderate in 81% and 66% of the cancers, respectively.
Nuclear MEIS2 expression was weak in about half of tumours
and moderate/strong in the other half. Cytoplasmic MEIS2
expression was weak in 33% and moderate in 62% of the
cancers.
Table 3 – Comparison of MEIS1, MEIS2 or PBX expression
between paired ovarian pre-and post-chemotherapy
tumour samples
N Tiesa Pb
After 3/6 cycles chemotherapy 26
Nuclear MEIS1 20 17 0.56
Nuclear MEIS2 20 16 1.00
Nuclear PBX 20 12 0.61
Cytoplasmic MEIS1 20 15 0.66
Cytoplasmic MEIS2 20 10 0.78
Cytoplasmic PBX 20 10 0.53
Recurrent disease 20
Nuclear MEIS1 19 18 0.32
Nuclear MEIS2 17 6 0.76
Nuclear PBX 18 8 0.53
Cytoplasmic MEIS1 19 13 1.00
Cytoplasmic MEIS2 18 9 0.32
Cytoplasmic PBX 18 5 0.32
a Ties: similar expression of MEIS1, MEIS2 or PBX between paired
ovarian pre- and post-chemotherapy tumour samples.
b Compared with primary ovarian cancer samples, Wilcoxon
paired test.
Table 2 – Nuclear and cytoplasmic MEIS and PBX protein expression in ovarian cancer samples
N NEa Weak Moderate Strong
Nuclear MEIS1
Primary 232 25 (11%) 2 (1%) 18 (8%) 187 (80%)
After 3/6 cycles chemotherapy 26 6 (23%) 0 (0%) 2 (8%) 18 (69%)
Recurrent disease 20 1 (5%) 0 (0%) 1 (5%) 18 (90%)
Cytoplasmic MEIS1
Primary 232 25 (11%) 27 (12%) 167 (72%) 13 (5%)
After 3/6 cycles chemotherapy 26 6 (23%) 0 (0%) 19 (73%) 1 (4%)
Recurrent disease 20 1 (5%) 1 (5%) 17 (85%) 1 (5%)
Nuclear MEIS2
Primary 232 29 (13%) 105 (45%) 88 (38%) 10 (4%)
After 3/6 cycles chemotherapy 26 6 (23%) 16 (62%) 4 (15%) 0 (0%)
Recurrent disease 20 2 (10%) 8 (40%) 10 (50%) 0 (0%)
Cytoplasmic MEIS2
Primary 232 29 (13%) 66 (28%) 126 (54%) 11 (5%)
After 3/6 cycles chemotherapy 26 6 (23%) 9 (35%) 10 (38%) 1 (4%)
Recurrent disease 20 2 (10%) 5 (25% 13 (65%) 0 (0%)
Nuclear PBX
Primary 232 25 (11%) 11 (5%) 42 (18%) 154 (66%)
After 3/6 cycles chemotherapy 26 6 (23%) 2 (8%) 8 (31%) 10 (38%)
Recurrent disease 20 2 (10%) 0 (0%) 5 (25%) 13 (65%)
Cytoplasmic PBX
Primary 232 25 (11%) 47 (20%) 136 (59%) 24 (10%)
After 3/6 cycles chemotherapy 26 6 (23%) 7 (27%) 10 (38%) 3 (12%)
Recurrent disease 20 2 (10%) 4 (20%) 12 (60%) 2 (10%)
All tumour sections wholly and homogeneously stained for MEIS and PBX.
a NE, not-evaluable.
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and PBX expression levels, as observed in the isogenic ovar-
ian cancer cisplatin resistance cell line model, their expres-sion levels were compared between paired pre- and post-
chemotherapy samples of 44 patients.15 Table 3 shows that
nuclear and cytoplasmic expression of MEIS1, MEIS2 and
PBX were not different between paired pre-chemotherapy
samples and samples obtained after three or six courses
of first-line chemotherapy, nor between paired pre-chemo-
therapy samples and samples obtained at surgery for recur-
rent disease.
From the univariate logistic regression analyses (Table 4)
it appeared that moderate/strong nuclear MEIS2 expression
was related with early stage (odds ratio 0.46 (0.25–0.87))
and grade 1 or 2 tumours (odds ratio 0.47 (0.26–0.85)). There
seemed to be a relation between strong nuclear MEIS1 (odds
ratio 0.38 (0.13–1.07)) or moderate/strong MEIS2 expression
(odds ratio 0.59 (0.34–1.03)) and non-serous ovarian cancers.
The multivariate logistic regression analysis for MEIS2
showed that stage (odds ratio 0.61 (0.26–1.44)), grade (odds
ratio 0.65 (0.32–1.33)) and histology (odds ratio 0.90 (0.46–
1.79)) were not independently related with MEIS2 expres-
sion. Moderate/strong nuclear MEIS2 expression was related
with a better overall survival (p = 0.036), whereas MEIS1
(p = 0.12) and PBX (p = 0.55) expression showed no relation
with survival. Fig. 2 shows the Kaplan–Meier overall survival
curves calculated for MEIS2. The multivariate Cox regres-
sion analyses adjusted for stage and residual tumour (Table
5) showed that MEIS 1 and 2 and PBX were not independent
prognostic factors for overall survival. The data for progres-
sion free survival were comparable to the results for overall
survival (not shown).
Table 4 – Results of the univariate logistic regression analysis for nuclear MEIS1, MEIS2 and PBX protein expression and









OR 95% CI OR 95% CI OR 95% CI
Age
> or 6 median age 1.25 0.49–3.20 1.18 0.68–2.06 1.53 0.81–2.89
Stage
III/IV or I/II 0.42 0.12–1.48 0.46 0.25–0.87a 0.67 0.33–1.40
Histologic type
serous or non-serous 0.38 0.13–1.07 0.59 0.34–1.03 0.85 0.45–1.60
Grade
3/undifferentiated or 1/2 0.84 0.33–2.16 0.47 0.26–0.851 0.57 2.91–1.12
Residual disease
>2 cm or 62 cm 0.86 0.33–2.22 0.92 0.52–1.62 0.96 0.50–1.84
a p < 0.02.
Table 5 – Results of multivariate Cox regression overall
survival analysis for nuclear MEIS1, MEIS2 and PBX
protein expression in ovarian cancer adjusted for stage
and residual tumour (hazard ratios (HR) and 95% CI)
TALE protein Overall survival
HR 95% CI
Nuclear MEIS1 (strong or weak/moderate) 1.00 0.54–1.83
Nuclear MEIS2 (moderate/strong or weak) 0.87 0.60–1.26
Nuclear PBX (strong or weak/moderate) 0.89 0.59–1.34
Fig. 2 – The Kaplan–Meier overall survival curves calculated
for MEIS2. Moderate/strong nuclear MEIS2 expression (––)
was related with a better overall survival (p = 0.036) in
ovarian cancer patients (all stages). Weak nuclear MEIS2
expression: (----) curve.
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Affymetrix data sets of normal (N353) and tumour
(XPO1026) tissue of different origins
The average expression of the MEIS1, MEIS2, MEIS3 (in silico
identified sequence), PBX1, PBX2, PBX3 and PBX4 genes in nor-
mal tissue ranges from 53–1249, 60–1792, 15–333, 162–2580,
62–303, 99–774 to 7–364, respectively (see Table 6). In normal
ovary average expression of MEIS1 (559, standard error (SE):
93) and MEIS2 (489, SE: 72) is comparable. Furthermore, PBX1
(898, SE: 60) and PBX3 (747, SE: 183) seem to be well expressed
in normal ovarian tissue compared to PBX2 (248, SE: 34) and
PBX4 (55, SE: 36).
The average expression of MEIS1, MEIS2, MEIS3, PBX1,
PBX2, PBX3 and PBX4 in cancer ranges from 86–1018, 178–
865, 34–147, 299–899, 64–228, 72–927 to 24–95, respectively
(Table 7). In ovarian cancer average MEIS1 expression (902,
SE: 111) is much higher than average MEIS2 expression (353,
SE: 50). Additionally, of the four PBX genes PBX1 has the high-
est expression (685, SE: 46). Moreover, the average expression
of MEIS1 in ovarian and uterine cancer and in neuroblastoma
and medulloblastoma is high compared to the other tumour
types (Table 7 and Fig. 3).
4. Discussion
This study shows that in ovarian carcinomas MEIS1, MEIS2
and PBX proteins are extensively expressed, both nuclear
and cytoplasmic. In normal ovarian surface epithelium, how-
ever, MEIS1 and 2 only stained nuclear. Additionally, MEIS1
RNA is much higher expressed in ovarian cancer compared
to other tumour types.
These specific findings in ovarian cancer are of interest as
MEIS1 and 2 and PBX could be important in ovarian oncogen-
esis by potentiating the function of aberrantly expressed HOX
proteins.5,26–28 When a HOX protein forms a complex with a
MEIS and a PBX protein, they show powerful downstream tar-
get promoter regulation as their DNA-binding affinities and
specificities are increased significantly.29,30 Co-activation of
HOXA9 and MEIS1 in mouse bone marrow cells has been re-
Table 6 – Average gene expression of MEIS and PBX in various normal tissues (N353 Affymetrix data set)
Tissue type Na MEIS1 MEIS2 MEIS3b PBX1 PBX2 PBX3 PBX4
Expc SEd Exp SE Exp SE Exp SE Exp SE Exp SE Exp SE
Adipose tissue 3 140.7 64.5 241.3 54.9 43.7 18.7 411.1 20.2 121.5 32.0 185.4 30.1 39.0 21.6
Adipose omental
tissue




3 96.5 20.1 184.2 37.6 62.5 20.5 485.1 65.9 109.8 16.8 167.6 5.3 42.7 17.1
Adrenal gland
cortex
4 804.0 94.3 1161.4 105.4 38.4 12.7 954.08 116.3 120.3 14.7 590.8 65.5 7.1 1.1
Bone marrow 5 89.4 17.8 59.5 3.0 58.5 14.5 201.7 38.7 298.2 48.4 130.2 5.7 16.4 2.0
Bronchus 3 377.6 70.0 268.4 43.3 100.0 19.0 413.9 57.7 155.3 43.6 174.3 10.0 61.3 6.4
Cerebellum 9 408.8 28.7 263.7 13.9 56.3 14.1 416.0 26.3 164.4 16.8 131.7 15.0 25.4 5.4
Cerebral cortex 9 112.0 19.5 410.4 36.9 118.1 19.8 595.2 33.3 171.2 18.4 124.3 19.4 21.1 6.1
Cerebrum 143 134.9 6.4 505.3 41.7 93.7 8.0 514.2 11.7 163.5 4.6 233.5 10.5 26.0 1.6
Cervix 4 1208.5 107.0 749.5 79.7 98.1 11.9 1723.3 149.7 179.9 14.3 449.4 45.9 29.9 8.3
Colon caecum 3 398.2 74.5 392.6 91.5 32.5 8.5 645.8 100.0 149.3 8.6 246.9 56.0 49.5 16.6
Coronary artery 3 110.0 6.6 559.9 48.8 63.3 11.0 546.1 45.0 302.7 121.8 216.6 47.1 30.1 12.7
Dorsal root ganglia 8 71.1 8.3 147.5 15.8 61.5 9.1 293.8 12.3 159.9 13.1 287.7 16.6 27.0 3.2
Endometrium 4 1210.4 166.5 737.7 408.0 209.8 63.0 1424.0 487.0 274.9 61.2 171.4 45.0 43.5 13.8
Oesophagus 4 524.2 68.4 352.6 48.3 50.3 17.0 888.6 113.6 150.3 26.4 264.2 38.8 33.4 5.4
Heart atrium 4 260.0 31.4 436.8 19.1 35.6 7.4 615.7 39.3 208.0 46.9 466.6 72.8 11.9 5.3
Heart ventricle 3 197.2 40.1 605.3 119.8 23.0 5.2 589.1 78.0 175.5 15.4 272.6 41.3 21.2 11.2
Kidney cortex 4 98.7 18.0 372.3 24.0 20.4 1.0 629.0 29.6 132.3 19.1 98.7 12.6 30.2 10.2
Kidney medulla 4 144.3 21.6 509.8 53.2 28.3 8.4 625.3 65.5 120.1 11.7 136.2 13.9 67.8 5.9
Liver 4 81.2 16.5 207.9 26.6 15.0 1.2 210.0 28.2 115.9 11.5 213.3 29.7 14.7 3.5
Lung 3 453.8 20.7 407.5 19.5 39.0 13.9 425.3 37.7 154.2 35.1 230.0 26.3 51.2 23.7
Lymph nodes 4 283.6 184.8 515.7 162.9 48.3 10.3 460.2 167.7 168.0 14.3 272.0 94.5 91.0 30.2
Mammary gland 3 146.4 14.1 358.9 76.1 63.4 8.5 689.0 87.9 167.6 24.2 203.8 40.7 31.1 14.8
Myometrium 5 1249.1 199.8 1792.2 200.5 333.1 69.4 2580.0 272.8 296.9 93.2 252.3 29.2 16.2 5.5
Nipple
cross-section
4 194.6 35.8 421.8 45.6 50.8 12.7 1033.9 88.1 215.3 39.0 185.7 12.3 43.4 6.5
Nodose nucleus 8 243.9 17.0 269.4 22.5 32.8 6.4 368.1 19.2 172.6 19.3 368.7 25.9 11.6 2.7
Oral mucosa 4 281.0 44.6 159.4 6.1 39.0 5.1 646.4 44.2 143.6 31.2 214.0 50.1 38.0 11.0
Ovary 4 559.4 92.9 488.6 72.0 79.6 13.7 898.4 60.2 248.4 33.5 774.4 182.6 54.9 35.6
Pharyngeal
mucosa
4 463.8 81.8 392.7 51.2 48.8 9.8 379.4 31.1 117.4 10.3 99.1 15.7 44.2 10.0
Pituitary gland 8 105.3 48.1 648.7 85.1 100.2 19.4 745.1 72.5 239.0 27.9 237.2 31.9 50.7 10.0
Prostate gland 3 302.3 63.4 1347.0 70.5 84.6 12.5 893.8 102.6 134.8 22.3 436.5 14.4 39.6 9.7
Salivary gland 4 648.5 55.6 1234.3 106.8 41.2 11.8 877.8 14.7 130.0 20.5 351.0 23.3 14.0 4.6
Saphenous vein 3 106.1 16.1 446.3 113.4 55.4 9.0 652.4 65.3 179.8 26.2 192.0 33.0 12.2 1.5
Skeletal muscle 5 98.4 12.2 90.7 13.2 36.3 9.4 588.1 37.2 128.1 22.5 101.8 15.3 17.4 3.9
Spinal cord 8 191.0 9.8 365.3 14.6 52.0 7.3 493.1 32.5 111.9 14.1 412.0 17.5 26.4 7.3
Spleen 4 245.3 26.6 309.4 60.9 36.1 9.9 338.4 39.8 162.0 23.2 240.9 24.8 60.1 8.0
Stomach cardiac 3 491.9 306.7 370.3 150.2 25.8 7.7 792.0 228.0 197.5 16.2 328.7 88.0 46.8 11.6


















































































































































































































































































































































































































































































































































































































































































































































































































































































































2502 E U R O P E A N J O U R N A L O F C A N C E R 4 3 ( 2 0 0 7 ) 2 4 9 5 –2 5 0 5ported to rapidly induce acute myeloid leukaemia, an effect
not observed with over-expression of these homeobox genes
alone.31 In ovarian carcinomas the effect of co-activation of
HOX, MEIS and PBX has not yet been investigated, although
aberrant expression of HOX RNA and proteins has been dem-
onstrated. In ovarian cancer the HOXA9–11 proteins are ex-
pressed according to a subtype-specific pattern, whereas
they are absent in normal ovarian surface epithelium. The
ability of HOXA9–11 to induce differentiation along their
respective pathways was shown to be promoted by HOXA7.26
Additionally, HOXB7 and HOXB13 genes were found to be over-
expressed in ovarian cancer cell lines and cancers compared
to whole normal ovaries and invasive characteristics of the
ovarian cancer SKOV3 cells were found to be suppressed by
the expression of anti-sense HOXB7 and HOXB13 mRNA.28
As we have shown that MEIS and PBX proteins are frequently
expressed in ovarian carcinomas they may potentiate the ef-
fect of these aberrantly expressed HOX genes on their target
genes.
Moreover, there is evidence that HOX, MEIS and PBX genes
are involved in oncogenic processes, such as chromatin bind-
ing, cell cycle control, proliferation, apoptosis, angiogenesis
and cell–cell communications.3,7,25,28,32–39 It has been shown
that in the normal endometriumMEIS1 protein was expressed
in early proliferative glandular epithelium and was absent
throughout the rest of the cycle, suggestive of a function in
proliferation for MEIS1.25 Furthermore, after exposure of the
ovarian surface epithelium cell line MCV152 to follicle-stimu-
lating hormone, cell proliferation was increased and MEIS1
expression was up-regulated.37 Constitutive over-expression
of MEIS1 may thus promote tumour growth in endometrial
and ovarian cancer. This is supported by the finding that
MEIS1 RNA is highly expressed in these cancer types.
In Drosophila, MEIS protein is necessary for nuclear local-
isation of PBX, which is exported to the cytoplasm in the ab-
sence of MEIS, and this mechanism was initially confirmed in
mammalian cells for both MEIS1 and MEIS2.40,41 A later report
however, indicates that nuclear localisation of PBX1 can also
be regulated independently of MEIS proteins.42 Interestingly,
in normal endometrial epithelium cells in the developing fe-
male genital tract, PBX1 can be cytoplasmic even in the pres-
ence of MEIS, possibly in correlation with the cell cycle.43 It is
therefore difficult to speculate whether our finding that the
localisation of MEIS1 and 2 in ovarian cancers is both nuclear
and cytoplasmic compared to nuclear in normal ovarian sur-
face epithelium is important for their function as well as the
function of PBX. Further research has to elucidate the mech-
anisms and meaning of MEIS and PBX localisation in both
normal and tumour tissues of the female genital tract.
In the present study MEIS1 and PBX RNA and protein were
higher expressed than MEIS2, indicating that these are the
main HOX cofactors present in ovarian cancers. Univariate
analysis showed that moderate/strong nuclear MEIS2 protein
expression was related to early stage and non-serous cancers
and also associated with better overall survival. An explana-
tion for the lack of relation between nuclear MEIS1 and PBX
and clinicopathologic characteristics or survival may be the
similar expression pattern in all ovarian cancers.
Analyses of paired samples before and after chemotherapy
showed that, the expression of all three proteins was not
Table 7 – Average gene expression of MEIS and PBX in various tumour types (XPO1026 Affymetrix data set)
Tumour type Na MEIS1 MEIS2 MEIS3b PBX1 PBX2 PBX3 PBX4
Expc SEd Exp SE Exp SE Exp SE Exp E Exp SE Exp SE
Bladder 8 149.7 21.2 274.0 59.5 40.6 8.4 396.8 85.7 172.9 3 2 201.7 28.9 53.8 9.7
Breast 207 105.1 6.9 197.6 11.6 68.9 2.6 898.7 35.7 167.9 8 204.6 8.8 29.8 1.3
Cervix 10 206.6 40.7 288.4 32.0 50.9 13.4 576.0 130.2 183.8 2 2 204.6 24.6 46.4 10.0
Colon 146 177.7 23.3 190.4 9.9 39.7 2.4 349.4 12.4 151.0 8 154.8 5.3 48.5 1.8
Corpus uteri 7 517.9 221.0 691.6 270.2 67.4 26.2 792.7 80.8 152.9 4 7 249.7 108.0 37.16 12.7
Endometrium 63 772.9 61.5 457.6 50.9 51.5 5.3 703.8 58.3 179.4 4 112.2 19.0 37.2 2.5
Kidney 112 116.5 8.0 349.5 34.1 37.3 3.0 310.7 12.4 196.9 1 138.6 5.3 37.4 2.3
Liver 16 142.8 35.1 177.8 46.0 41.9 7.3 342.2 52.7 172.9 1 3 173.5 16.6 46.8 3.6
Lung 74 157.2 9.6 268.0 32.6 46.0 3.9 386.7 29.1 177.1 4 212.2 15.2 42.1 2.6
Medulloblastoma 51 384.9 109.5 715.7 74. 130.9 5.8 298.9 55.9 64.2 2 3 123.5 10.3 95.0 3.9
Neuroblastoma 110 965.4 76.4 864.8 40.7 147.0 4.2 452.2 36.6 120.4 1 0 401.4 13.1 40.3 2.6
Omentum 36 1018.2 24.6 429.0 76.0 57.5 5.4 692.2 47.5 227.6 1 3 147.4 33.5 47.9 2.4
Ovary 98 902.0 110.8 353.3 50.4 42.0 7.1 685.1 45.6 193.1 1 4 177.4 19.1 42.7 4.2
Prostate 20 198.9 39.4 671.7 47.9 41.2 8.4 564.7 49.7 173.3 1 8 475.0 33.3 23.5 10.9
Rhabdomyosarcoma 9 282.7 26.0 427.7 49.8 61.4 7.4 464.4 78.7 61.7 2 9 138.0 36.7 140.6 8.4
Rectosigmoid 19 274.6 103.6 224.2 189.5 41.9 12.1 400.8 245.0 182.7 1 9 153.5 61.6 36.4 12.0
Rectum 19 150.2 87.2 188.4 306.0 48.2 9.1 335.9 132.8 158.7 2 4 169.4 58.7 64.4 12.8
Renal pelvis 8 132.6 28.4 327.9 58.9 35.1 5.5 453.7 65.5 194.4 3 3 132.6 353.7 61.8 18.9
Small intestine 10 267.2 43.7 59.23 83.9 57.2 11.1 678.5 98.0 202.7 1 6 280.7 59.9 50.7 6.7
Stomach 6 375.4 82.3 609.9 75.6 34.4 8.3 522.2 74.8 155.6 2 9 252.3 12.4 45.9 3.5
Thyroid 14 86.5 21.2 246.7 59.5 35.9 8.4 588.8 85.7 182.8 3 2 927.2 28.9 81.1 9.7
Urinary bladder 7 200.3 6.9 382.6 11.6 62.8 2.6 746.4 35.7 141.0 8 228.3 8.8 49.7 1.3
Uterus 14 679.1 40.7 535.8 32.0 40.2 13.4 615.9 130.2 177.1 2 2 71.5 24.6 28.8 10.0
a N: number of tumour samples.
b In silico identified MEIS3 sequence.
c Exp: average expression.


































































Fig. 3 – Bar diagram showing average MEIS1 RNA expression in ovarian tumours and various other tumour types based on
analysis of the public human Affymetrix data set XPO1026. The dashed bars correspond to the average MEIS1 expression in
ovarian cancer (omentum and ovary). The error bars represent the standard error of MEIS1 expression. The average
expression of MEIS1 in ovarian cancer is high compared to most other tumour types.
2504 E U R O P E A N J O U R N A L O F C A N C E R 4 3 ( 2 0 0 7 ) 2 4 9 5 –2 5 0 5influenced by preceding first-line chemotherapy and not dif-
ferent at the time of recurrence in paired cancers. In our mi-
cro-array study of four ovarian cancer cell lines, MEIS1 and 2
and PBX3 gene expression were associated with cisplatin
resistance.15 This may be due to the fact that availability of
paired patient samples only occurs in the case of residual
and resistant disease.
Targeting of MEIS1 or 2 or PBX may impair the oncogenic
function of various aberrantly expressed HOX proteins at
once. Although targeting of homeobox proteins with drugs
is momentarily not possible, targeting MEIS1 or 2 or PBX
in vitro with siRNA is an option. As MEIS1 appears to be so
highly expressed in ovarian cancers compared to other cancer
types especially this gene seems the most interesting candi-
date for targeted therapy.
It is important in future research to discover aberrantly ex-
pressed HOX genes in ovarian cancer and how their function
is enforced by their cofactorsMEIS1 and 2 and PBX. This could
lead to insight in how oncogenic HOX function would be abol-
ished by targeting MEIS1 and 2 and PBX.
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